Contribution of HOGG1 Ser^{326}Cys Polymorphism to the Development of Prostate Cancer in Smokers: Meta-Analysis of 2779 Cases and 3484 Controls

Bin Xu^{1,2}, Na Tong^{3}, Shu-Qiu Chen^{1}, Yu Yang^{1}, Xiao-Wen Zhang^{1}, Jin Liu^{1}, Xiang-Nong Hu^{1}, Guo-Zhu Sha^{1}, Ming Chen^{1,2}

1 Department of Urology, Affiliated Zhongda Hospital, Southeast University, Nanjing, China, 2 Surgical Research Center, Medical School, Southeast University, Nanjing, China, 3 Department of Occupational Medicine and Environmental Health, Nanjing Medical University, Nanjing, China

Abstract

The HOGG1 gene catalyzes the excision of modified bases and removal of DNA damage adducts. It may play an important role in the prevention of carcinogenesis. Ser^{326}Cys polymorphism localizes in exon 7 of the hOGG1 gene. It takes the form of an amino acid substitution, from serine to cysteine, in codon 326. Several epidemiological association studies have been conducted on this polymorphism and its relationship with the risk of prostate cancer. However, results have been conflicting. To resolve this conflict, we conducted a meta-analysis on the association between this polymorphism and prostate cancer, taking into account race, country, sources of controls, and smoking status. A total of nine studies covering 2779 cases and 3484 controls were included in the current meta-analysis. Although no significant association was found between hOGG1 Ser^{326}Cys polymorphism and prostate cancer susceptibility in the pooled analysis, individuals with Ser/Cys/Cys genotypes were found to have greater risk of prostate cancer if they were also smokers (OR = 2.66, 95% CI = 1.58–4.47) rather than non-smokers (OR = 2.18, 95% CI = 1.13–4.19), compared with those with Ser/Ser genotype. In conclusion, our meta-analysis demonstrates that hOGG1 Ser^{326}Cys polymorphism is a risk factor for prostate cancer in smokers. Further studies are needed to confirm this relationship.

Introduction

Oxidative DNA damage is involved in carcinogenesis. It causes mutations that can inactivate tumor suppressor genes and activate oncogenes. The major form of DNA adduction induced by oxidative damage is 8-OH-dG (8-hydroxy-2-deoxyguanosine) and increased 8-OH-dG formation in DNA results in mutagenesis and carcinogenesis [1]. A DNA glycosylase/apurinic-apyrimidinic lyase encoded by the human oxoguanine glycosylase 1 (hOGG1) gene catalyzes the excision of modified bases and removal of 8-OH-dG adducts and has been hypothesized to play an important role in the prevention of carcinogenesis [2].

Prostate cancer is most commonly-diagnosed malignancy in elderly men in developed countries, and the incidence increases every year. Deficient DNA repair mechanisms may play a role in the age-related increase in prostate cancer risk by allowing carcinogenic DNA damage events to accumulate uncorrected. Higher levels of 8-OH-dG and downregulation of hOGG1 also have been observed in benign prostatic hyperplasia (BPH) and prostate cancer.

Variations in the hOGG1 gene have been identified and the repair activities of the variant proteins have been evaluated in several studies. One of the most frequently analyzed variations is in exon 7 of the hOGG1 gene, which takes the form of a single amino acid substitution, from serine to cysteine at codon 326 (Ser^{326}Cys, rs1052133). The hOGG1 protein encoded by the Ser^{326} allele showed much more DNA repair activity than that encoded by Cys^{326} allele in vitro [3]. There have also been several epidemiological studies concerning the association between this variation and the risk of prostate cancer. However, the results have not been conclusive. For example, Chen et al. found that carriers with the Cys^{326} allele had a significantly increased risk of prostate cancer, but Xu et al. found that subjects with Cys^{326} allele had a reduced risk of prostate cancer. For this reason, we conducted a meta-analysis on hOGG1 Ser^{326}Cys polymorphism and the risk of prostate cancer, taking into account certain characteristics of the subjects and studies, such as race, country, source of controls and smoking status. We believe that this will help us better understand the risk of prostate cancer.

Materials and Methods

Publication search

The two online bibliographic databases (PubMed and Embase) were consulted with the following search strategy: “human oxoguanine glycosylase 1, hOGG1 or OGG1, hOGG or
OGG1, “polymorphism or variant,” and “prostate cancer or prostate neoplasm” (last search was updated on Oct. 27, 2011). Original studies in English on hOGG1 polymorphism in prostate cancer were included; reviews, editorials, and letters were excluded. All the references of relevant reviews and eligible articles that our search retrieved were checked carefully.

Inclusion criteria and data abstraction

Two investigators searched the literature and extracted data independently. The inclusion criteria were as follows: (i) Each study had to discuss or concern hOGG1 Ser326Cys polymorphism and the risk of prostate cancer. (ii) Each study had to use a case-control design. (iii) Each study had to contain information about available genotype frequency that could help technicians infer the results from the papers. For each of the eligible case-control studies, the following data were collected: the first author’s last name, year of publication, country of origin of the subjects, race of the subjects, sources of controls, smoking status of the subjects, number of genotyped cases and controls, and Hardy-Weinberg equilibrium status.

Statistical analysis

The association between hOGG1 different genotypes (including the heterozygote comparison Ser/Cys vs. Ser/Ser) and the homozygote comparison Cys/Cys vs. Ser/Ser), the dominant genetic model (Ser/Cys+Cys/Cys vs. Ser/Ser) and the recessive genetic model (Cys/Cys vs. Ser/Cys+Ser/Ser) and susceptibility to prostate cancer was measured using the crude odds ratio (OR) with related 95% confidence interval (CI). A χ²-based Q-test was used to check the heterogeneity of the current study and determine the methods for calculating OR. If P>0.05 for a given χ²test indicated a lack of heterogeneity among the studies, then the summary ORs were calculated using the fixed-effects model (the Mantel-Haenszel method). Otherwise, the random effects model (DerSimonian and Laird method) was used. The significance of the pooled OR was determined using the χ²-test, and P<0.05 was considered statistically significant. Subgroup analyses were also conducted on the basis of subject race, country, source of controls, and smoking status. The statistical power was calculated using PS software [http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/PowerSampleSize].

The publication bias was determined using Egger’s linear regression test by visual inspection of the Funnel plot. All statistical analyses were performed using Stata 10.0 (StataCorp LP, College Station, TX, U.S.).

Results

Study characteristics

Characteristics of eligible studies are presented in Table 1 [4–12]. In all, 6,968 papers were retrieved by searching for the terms listed above (PubMed: 3,464 and Embase: 3,504). The study selection process is shown in Fig. 1. Nine studies with 2779 cases and 3484 controls were included in present meta-analysis [4–12].

Four studies had been conducted on Caucasians, one on Asians, one study on Africans, and three in mixed populations (Caucasians and African Americans). Six studies were population-based [4,5,8,10–12]. The others were hospital-based [6,7,9]. In the hospital-based studies, controls were all selected from among patients without any sign of any type of cancer. The distribution of genotypes among controls was consistent with Hardy-Weinberg equilibrium in all studies except two [8,9]. Two studies collected information on possible confounding factors like smoking status [4,6]. In this way, the association between the Ser326Cys
polymorphism and prostate cancer was separately evaluated among smokers and non-smokers. However, these two studies only provided the frequency data regarding Ser/Cys+Cys/Cys and Ser/Ser genotypes. For this reason, only a comparison of Ser/Cys+Cys/Cys vs. Ser/Ser was conducted.

Meta-analysis

The main results of the current study on the association between hOGG1 Ser326Cys polymorphism and the risk of prostate cancer are shown in Table 2. Overall, no significant association with prostate cancer was observed using a random effects model in the comparisons of Ser/Cys to Ser/Ser (OR = 1.09, 95% CI: 0.93–1.28; $P_{\text{heterogeneity}}/P = 0.047/0.409$), Cys/Cys vs. Ser/Ser (OR = 0.91, 95% CI: 0.53–1.52; $P_{\text{heterogeneity}}/P = 0.001/0.449$), Ser/Cys+Cys/Cys vs. Ser/Ser (OR = 1.12, 95% CI: 0.92–1.37; $P_{\text{heterogeneity}}/P = 0.002/0.271$), or Cys/Cys vs. Ser/Cys+Ser/Ser (OR = 1.03, 95% CI: 0.66–1.60; $P_{\text{heterogeneity}}/P = 0.001/0.913$) in the pooled analysis (Fig. 2). We did not find any significant results when we stratified the studies by race, country, or source of the controls.

Genotype information of the Ser326Cys polymorphism stratified by smoking status was available in two papers. As shown in Fig. 3, individuals with Ser/Cys+Cys/Cys genotypes showed more pronounced increased prostate cancer risk if they were smokers (OR = 2.66, 95% CI: 1.58–4.47; $P_{\text{heterogeneity}}/P = 0.365/0.019$) rather than non-smokers (OR = 2.18, 95% CI: 1.13–4.19; $P_{\text{heterogeneity}}/P = 0.095/0.001$), relative to those with the Ser/Ser genotype.

Sensitivity analysis and publication bias

Sensitivity analysis was conducted to assess the influence of each study on the pooled OR by omission of individual studies. As shown in Fig. 4, the results suggested that no individual study would significantly affect the overall OR. Funnel plots and Egger’s test (Fig. 5) were used to assess publication bias. The results indicated that there was no evidence of publication bias ($t = 2.08$, $P = 0.076$ for Ser/Cys vs. Ser/Ser).

Discussion

The potential role of hOGG1 Ser326Cys polymorphism as a determinant of prostate cancer risk was investigated in a sample of 6263 subjects from nine published case-control studies. However, no significant association was found under any genetic model in the overall analysis. Ever since the hOGG1 Ser326Cys polymorphism was found to occur frequently in human populations, studies on this polymorphism and the risk of cancer have been conducted and published. Xu et al. first found this polymorphism to be associated with the risk of prostate cancer in a Caucasian population in 2002 [5]. After that, several investigators duplicated his work in different populations. However, the results remained confusing, even within the same population. While we were preparing the present study, a meta-analysis for this same polymorphism was published by Zhang et al. Their study included 8 papers with 2584 cases and 3234 controls, and they found an association between hOGG1 Ser326Cys polymorphism and prostate cancer in an African-Caucasian-mixed population. In the current study, we retrieved 9 papers with more subjects and we also stratified the analyses not only by race, country, but also by smoking status. We found that the Cys326 allele was associated with a more pronounced increased risk of prostate cancer in smokers than in non-smokers.

HOGG1 is a key protein involved in base excision repair. It recognizes and excises lesions from oligodeoxynucleotides with DNA damage. Recently, studies have suggested that the hOGG1 Cys326 allele may be associated with an increased risk and severity of many types of cancer [13]. These results are likely to support the hypothesis that a minimally active hOGG1*Cys326 allozyme lacks the ability to repair the DNA damage induced by environmental chemicals in carcinogenesis. However, the exact repair function associated with this polymorphism remains unclear. Kohno et al. observed that the Cys326 allele was less capable of complementing a repair-deficient strain than the Ser326 allele, while Dherin et al. found no significant differences in hOGG1 protein enzymatic activity in vitro [3,14]. Janssen et al. found that DNA repair activity of hOGG1 in lymphocytes was not dependent on the
Table 2. Stratified analyses of the hOGG1 Ser326Cys polymorphism on prostate cancer risk.

| Variables          | n  | MAF | Power | Cases/controls | Ser/Cys vs. Ser/Ser | Cys/Cys vs. Ser/Ser | Ser/Cys+Cys/Cys vs. Ser/Ser | Cys/Cys vs. Ser/Cys+Cys/Ser/Ser |
|--------------------|----|-----|-------|----------------|---------------------|---------------------|-----------------------------|--------------------------------|
|                    |    |     |       |                | OR (95% CI)         | OR (95% CI)         | OR (95% CI)                 | OR (95% CI)                  |
| Total              | 9  |     |       | 2779/3484      | 1.09 (0.93–1.28)    | 0.91 (0.55–1.52)    | <0.001/0.449                  | 1.03 (0.66–1.60)              |
| Race               |    |     |       |                |                     |                     |                             |                                |
| Caucasian          | 4  | 0.23 | 0.81  | 693/806        | 1.33 (0.92–1.93)    | 0.53 (0.130)        | <0.001/0.368                  | 1.47 (0.53–4.08)              |
| Others             | 5  | 0.25 | 0.07  | 2086/2678      | 0.99 (0.87–1.12)    | 0.86 (0.52–1.41)    | 0.014/0.543                   | 0.86 (0.53–1.39)              |
| Country            |    |     |       |                |                     |                     |                             |                                |
| USA                | 5  | 0.19 | 0.77  | 1206/1745      | 1.18 (0.88–1.58)    | 1.41 (0.68–2.94)    | <0.001/0.357                  | 1.25 (0.69–2.28)              |
| Others             | 4  | 0.30 | 0.07  | 1573/1739      | 1.05 (0.85–1.29)    | 0.85 (0.38–1.90)    | 0.008/0.699                   | 0.83 (0.40–1.75)              |
| Sources of controls|    |     |       |                |                     |                     |                             |                                |
| Hospital-based     | 3  | 0.30 | 0.95  | 1378/1489      | 1.23 (0.81–1.87)    | 0.26/0.335          | <0.001/0.453                  | 1.25 (0.59–2.66)              |
| Population-based   | 6  | 0.20 | 0.09  | 1401/1995      | 1.06 (0.89–1.26)    | 0.30/0.497          | 0.256/0.041                   | 0.90 (0.49–1.66)              |
| Smoke status       |    |     |       |                |                     |                     |                             |                                |
| Non-smokers        | 2  | 0.19 | 0.60  | 60/127         | -                   | -                   | 2.18 (1.13–4.19)              | 0.365/0.019                   |
| Smokers            | 2  | 0.17 | 0.95  | 110/220        | -                   | -                   | 2.66 (1.58–4.47)              | 0.095/0.001                   |

*Number of comparisons.

<sup>p</sup> Value of Q-test for heterogeneity test.

<sup>c</sup>Random-effects model was used when <sup>p</sup>-value for heterogeneity test < 0.05; otherwise, fixed-effects model was used.

doi:10.1371/journal.pone.0030309.t002
Ser326Cys polymorphism [15]. Our results showed that the hOGG1 Cys326 allele was not associated with the risk of prostate cancer, confirming that the enzymatic activity of hOGG1 might not be determined by Ser326Cys polymorphism alone. Rather, it is possible that other confounding factors might interact with this polymorphism in the process of DNA repair.

Although cigarette smoking has been found to be involved in many cancers and is one of the leading causes of cancer-related death, its role in prostate cancer remains ill-defined [16]. Recently, a meta-analysis of 24 prospective cohort studies found smoking to be associated with higher risk of developing and dying of prostate cancer [17]. Ngo et al. also found that smoking not only independently predicted greater tumor volumes and higher grades in prostate cancer but also a greater risk of biochemical recurrence after radical prostatectomy [18]. Moreover, smoking was found to have a destructive effect on DNA [19]. In the present study, gene-environment interaction was also investigated between hOGG1 Ser326Cys polymorphism, cigarette smoking, and risk of prostate cancer. We found that the risk effect of Ser/Cys+Cys/Cys genotypes was more pronounced among smokers than among non-smokers. The powers of the subtype analyses were 0.60 in the non-smoker group and 0.95 in the smoker group, suggesting an interaction between the hOGG1 polymorphism and smoking with respect to prostate cancer. Such an interaction is reasonable.
considering that the hOGG1 protein protects cells against the reactive oxygen species and DNA adducts that can be caused by from cigarette smoking. The Cys326 allele has been reported to be associated with decreased DNA repair activity. For this reason this allele was thought to be a risk factor for smokers.

The current study has some shortcomings that should be addressed. First, the U.S., Canadian, and Australian populations were classified as Caucasian. However, populations in these areas consist both of indigenous peoples and many types of immigrants, and not all of the studies stated the ancestries of their participants clearly. Second, the controls were not uniform either. In hospital-based studies, most of the controls were BPH patients. Some individuals in the control group might be likely to develop cancer in subsequent years, even if they showed no clinical symptoms at the time of investigation. Misclassification bias can cause deviated genotype distribution in the controls. In spite of these, the present meta-analysis also had some advantages over previous studies. For the first time, we conducted a meta-analysis on hOGG1 polymorphism on prostate cancer susceptibility while considering possible confounding factors, such as smoking status, by polling the results of all published independent studies. The statistical power of the analysis is greater than that of any single study, although it remains relatively small. The quality of studies included in our meta-analysis was satisfactory and perfectly met our inclusion criteria.

In conclusion, our meta-analysis demonstrates that hOGG1 Ser326Cys polymorphism is a risk factor for prostate cancer in smokers. Further studies are needed to confirm the relationship.
We believe that these results will foster comprehensive understanding of the association between hOGG1 polymorphism and the risk of prostate cancer with respect to gene-gene and gene-environment interactions.

References

1. Kamiya H, Miura K, Ishikawa H, Inoue H, Nishimura S, et al. (1992) c-Ha-ras containing 8-hydroxyguanine at codon 12 induces point mutations at the modified and adjacent positions. Cancer Res 52: 5483–5485.

2. Boiteux S, Radielle JP (2000) The human OGG1 gene: structure, functions, and its implication in the process of carcinogenesis. Arch Biochem Biophys 377: 1–8.

3. Kohno T, Shimura K, Tosa M, Tani M, Kim SR, et al. (1998) Genetic polymorphisms and alternative splicing of the hOGG1 gene, that is involved in the repair of 8-hydroxyguanine in damaged DNA. Oncogene 16: 3219–3225.

4. Chen L, Ehlali A, Pow-Sang J, Lazarus P, Park J (2003) Association between polymorphism of human ooxguanine glycosylase 1 and risk of prostate cancer. J Urol 170: 2471–2474.

5. Xu J, Zheng SL, Turner A, Isaacs SD, Wiley KE, et al. (2002) Associations between hOGG1 sequence variants and prostate cancer susceptibility. Cancer Res 62: 2253–2257.

6. Dhillon VS, Yeoh E, Fenech M (2009) DNA repair gene polymorphisms and prostate cancer risk in South Australia-results of a pilot study. Urol Oncol.

7. Yun SJ, Ha YS, Chae Y, Kim JS, Kim JY, et al. (2011) The hOGG1 mutant genotype is associated with prostate cancer susceptibility and aggressive clinicopathological characteristics in the Korean population. Ann Oncol.

8. Noell NL, Czek MS, Li L, Liu X, Rybicki BA, et al. (2006) Polymorphisms in estrogen bioactivation, detoxification and oxidative DNA base excision repair genes and prostate cancer risk. Carcinogenesis 27: 1842–1848.

9. Nam RK, Zhang WW, Jewett MA, Trachtenberg J, Klotz LH, et al. (2005) The use of genetic markers to determine risk for prostate cancer at prostate biopsy. Clin Cancer Res 11: 8391–8397.

10. Zhang J, Dhakal IB, Greene G, Lang NP, Radilobar FF (2009) Polymorphisms in hOGG1 and XRCC1 and risk of prostate cancer: effects modified by plasma antioxidants. Urolgy 75: 779–785.

Author Contributions

Conceived and designed the experiments: BX MC. Performed the experiments: BX NT S-QG. Analyzed the data: BX YY X-WZ. Contributed reagents/materials/analysis tools: NT JL X-NH G-ZS. Wrote the paper: BX.

11. Lavender NA, Komolafe OQ, Benford M, Brock G, Moore JH, et al. (2010) No association between variant DNA repair genes and prostate cancer risk among men of African descent. Prostate 70: 113–119.

12. Mittal RD, Mandal RK, Gangwar R (2011) Base excision repair pathway genes polymorphism in prostate and bladder cancer risk in North Indian population. Mech Aging Dev.

13. Kim EJ, Yan C, Ha YS, Jeong P, Yi Kim I, et al. (2010) Analysis of hOGG1 genotype as a prognostic marker for muscle invasive bladder cancer: A novel approach using peptide nucleic acid-mediated, real-time PCR clamping. Urol Oncol.

14. Dherin C, Radielle JP, Dizdaroglu M, Boiteux S (1999) Excision of oxidatively damaged DNA bases by the human alpha-hOgg1 protein and the polymorphic alpha-hOgg1(Ser326Cys) protein which is frequently found in human populations. Nucleic Acids Res 27: 4001–4007.

15. Jansen K, Schlink K, Gotte W, Hippler B, Kaina B, et al. (2001) DNA repair activity of 8-oxoguanine DNA glycosylase 1 (OGG1) in human lymphocytes is not dependent on genetic polymorphism Ser326/Cys326. Mutat Res 486: 207–216.

16. Hickey K, Do KA, Green A (2001) Smoking and prostate cancer. Epidemiol Rev 23: 115–123.

17. Huncharek M, Haddock KS, Reid R, Kupelnick B, et al. (2001) DNA repair activity of 8-oxoguanine DNA glycosylase 1 (OGG1) in human lymphocytes is not dependent on genetic polymorphism Ser326/Cys326. Mutat Res 486: 207–216.

18. Ngo TC, Lee JJ, Brooks JD, Nolley R, Ferrari M, et al. (2011) Smoking and adverse outcomes at radical prostatectomy. Urol Oncol.

19. La Maestra S, Kishy GE, Micalle RT, Johnson J, Kow YW, et al. (2011) Cigarette Smoke Induces DNA Damage and Alters Base-Excision Repair and Tau Levels in the Brain of Neonatal Mice. Toxicol Sci.